Tolerance and autoimmunity

New England Journal of Medicine

Volumn 344, Issue 9, 2001, Pages 655-664

  Kamradt, Thomas ^a   Avrion Mitchison, N ^b  

^a DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; B LYMPHOCYTE RECEPTOR; B7 ANTIGEN; BETA INTERFERON; CD28 ANTIGEN; CD86 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS ANTIGEN; FAS LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VACCINE;

ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CLONAL ANERGY; CROHN DISEASE; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; THYMUS;

EID: 0035283175     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200103013440907     Document Type: Review

References (151)

1. Somatic generation of antibody diversity
2. Somatic recombination in a murine T-cell receptor gene
3. The immune system
4. The role of autoantibodies in autoimmune disease
5. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins
6. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme
7. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes
8. Expansion or elimination of B cells in vivo: Dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor
9. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice
10. Receptor selection in B and T lymphocytes
11. Self-reactive B cells are not eliminated or inactivated by autoantigen expressed on thyroid epithelial cells
12. T cell-independent rescue of B lymphocytes from peripheral immune tolerance
13. T-independent immune response: New aspects of B cell biology
14. B cells in autoimmunity
15. B-lymphocyte quiescence, tolerance and activation as viewed by global gene expression profiling on microarrays
16. Immunology: Lymphocyte survival - Ignorance is BLys
17. The "clonal selection hypothesis" and current concepts of B cell tolerance
18. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus
19. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes
20. A range of CD4 T cell tolerance: Partial inactivation to organ-specific antigen allows nondestructive thyroiditis or insulitis
21. Shaping of the autoreactive T-cell repertoire by a splice variant of self protein expressed in thymic epithelial cells
22. Myelin-specific T lymphocytes in multiple sclerosis patients and healthy individuals
23. T cell autoreactivity to insulin in diabetic and related non-diabetic individuals
24. Lymphocyte homing and homeostasis
25. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice
26. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: Role of anti-self (virus) immune response
27. Levels of peripheral T cell tolerance induced by different doses of tolerogen
28. Immunologically privileged sites
29. The immune system evolved to discriminate infectious nonself from noninfectious self
30. + T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity
31. Immune reponse to human papillomaviruses and the prospects for human papillomavirus-specific immunisation
32. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis
33. Limited capacity for tolerization of CD4+ T cells specific for a pancreatic beta cell neo-antigen
34. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family
35. Autocrine T-cell suicide mediated by APO-I/(Fas/CD95)
36. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas
37. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation
38. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity
39. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome
40. Fas ligand-induced apoptosis as a mechanism of immune privilege
41. Macrophage-dependent apoptosis ofCD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor
42. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
43. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin
44. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo
45. Peripheral tolerance in T cell receptor-transgenic mice: Evidence for T cell anergy
46. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
47. Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells anergized in vivo
48. Activation changes the spectrum but not the diversity of genes expressed by T cells
49. How self-tolerance and the immunosuppressive drug FK506 prevent B-cell mitogenesis
50. Costimulatory regulation of T cell function
51. Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells
52. Two genetic loci regulate T cell-dependent islet inflammation and drive autoimmune diabetes pathogenesis
53. High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice
54. Regulatory CD4(+) T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis
55. CD4(+) T cells prevent spontaneous experimental autoimmune encephalomyelitis in anti-myelin basic protein T cell receptor transgenic mice
56. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis
57. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD4SRB(Iow) CD4+ T cells
58. - thymocytes
59. Immunologic self-tolerance maintained by CD2S (+) CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
60. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes
61. Regulatory T cells in autoimmunity
62. Epidemiologic evidence for multiple sclerosis as an infection
63. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading
64. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis
65. T cell stimulation in vivo by lipopolysaccharide (LPS)
66. Microbial lipopeptides induce the production of IL-17 in Th cells
67. Pertussis toxin prevents the induction of peripheral T cell anergy and enhances the T cell response to an encephalitogenic peptide of myelin basic protein
68. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma
69. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA
70. Diabetes induced by Coxsackie virus: Initiation by bystander damage and not molecular mimicry
71. Molecular mimicry in virus infection: Crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments
72. Molecular mimicry and autoimmunity
73. Sequence homology between certain viral proteins and proteins related to encephalomyelitis and neuritis
74. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: Mechanism for autoimmunity
75. Arthritis induced by a T-lymphocyte clone that responds to Mycobacterium tuberculosis and to cartilage proteoglycans
76. Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology
77. Crossreactivity of myelin basic protein-specific T cells with multiple microbial peptides: Experimental autoimmune encephalomyelitis induction in TCR transgenic mice
78. Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease
79. Multiple cross-reactive self-ligands for Borrelia burgdorferi-specific HLA-DR4-restricted T cells
80. Early infection and subsequent insulin dependent diabetes
81. Risk factors for allergy
82. T cells recognizing multiple peptides of myelin basic protein are found in blood and enriched in cerebrospinal fluid in optic neuritis and multiple sclerosis
83. A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity
84. In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha
85. The NOD Idd9 genetic interval influences the pathogenicity of insulitis and contains molecular variants of Cd30, Tnfr2, and Cd137
86. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases
87. A second-generation screen of the human genome for susceptibility to insulin-dependent diabetes mellitus
88. A search for type 1 diabetes susceptibility genes in families from the United Kingdom
89. Genetics of multiple sclerosis
90. Genetic control of arthritis onset, severity and chronicity in a model for rheumatoid arthritis in rats
91. Epistatic modifiers of autoimmunity in a murine model of lupus nephritis
92. Positional cloning of the APECED gene
93. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains
94. Autoimmunity and immunodeficiency disease
95. A critical role for complement in maintenance of self-tolerance
96. Cutting edge: Clq protects against the development of glomerulonephritis independently of C3 activation
97. Regulation of interleukin (IL)-12 receptor beta2 subunit expression by endogenous IL-12: A critical step in the differentiation of pathogenic autoreactive T cells
98. High frequency of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice: Mechanisms of selection of the self-reactive repertoire
99. The NOD mouse model of type 1 diabetes: As good as it gets?
100. Immunological treatment of autoimmune diseases
101. Long-term clinical efficacy of grass-pollen immunotherapy
102. Insulin prophylaxis in individuals at high risk of type 1 diabetes
103. Clinical and immunologic effects of component peptides in Allervax Cat
104. Allergen immunotherapy: Therapeutic vaccine for allergic diseases
105. 90 in chronic progressive multiple sclerosis
106. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis
107. Treatment of uveitis by oral administration of retinal antigens: Results of a phase I/II randomized masked trial
108. Effects of oral administration of type II collagen on rheumatoid arthritis
109. Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis
110. Induction of autoimmune diabetes by oral administration of autoantigen
111. Experimental mucosal induction of uveitis with the 60-kDa heat shock protein-derived peptide 336-351
112. Treatment of murine lupus with CTLA4Ig
113. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells
114. IL-10 is a key cytokine in psoriasis: Proof of principle by IL-10 therapy: A new therapeutic approach
115. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
116. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75) Fc fusion protein
117. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease
118. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
119. Massive factor-VIII infusion in a haemophiliac with factor-VIII inhibitor, high responder
120. Immune tolerance in hemophilia-principal results from the International Registry: Report of the Factor VIII and LX Subcommittee
121. Cellular sites of immunologic unresponsiveness
122. Treatment of experimental allergic encephalomyelitis with encephalitogenic basic proteins
123. Studies on the chemistry of anaphylaxis III. Experiments with isolated proteins, expecially those of the hen's egg
124. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen
125. Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein
126. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin
127. Late complications of immune deviation therapy in a nonhuman primate
128. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: A multicentre randomised controlled trial
129. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy
130. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice
131. Altered peptide ligand-induced partial T cell activation: Molecular mechanisms and role in T cell biology
132. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells
133. T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis
134. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
135. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation
136. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: Requirement for both B7-1 and B7-2
137. The immune system
138. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy
139. Multiple sclerosis: Comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells
140. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease
141. T helper 2 (Th2) T cells induce acute pancreatitis and diabetes in immune-compromised nonobese diabetic (NOD) mice
142. Identification of autoantibodies associated with myelin damage in multiple sclerosis
143. Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation
144. Outcome of rheumatoid arthritis and psoriasis following autologous stem cell transplantation for hematologic malignancy
145. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: A phase I study
146. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy
147. Discovery and analysis of inflammatory disease-related genes using eDNA microarrays
148. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis
149. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
150. Innate immunity
151. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge